Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer
Abstract Pancreatic cancer (PC) is among the most aggressive malignancies associated with a 5-year survival rate of <9%, and the treatment options remain limited. Antibody–drug conjugates (ADCs) are a new class of anticancer agents with superior efficacy and safety profiles. We studied the antitu...
Main Authors: | Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-04-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-023-05820-1 |
Similar Items
-
Bivalent EGFR-Targeting DARPin-MMAE Conjugates
by: Lennard Karsten, et al.
Published: (2022-02-01) -
Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
by: Ce Yi, et al.
Published: (2023-12-01) -
Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
by: Yanming Wang, et al.
Published: (2019-07-01) -
Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
by: Yanming Wang, et al.
Published: (2020-03-01) -
1407 Expanding the therapeutic index of MMAE-based antibody-drug conjugates (ADCs) with a novel linker system (LD343)
by: Lei Wang, et al.
Published: (2023-11-01)